



### ▶ PHARMA POOL

**Randy MILBY**  
**Dr. Antony PFAFFLE**

#### CORMEDIX ANNOUNCES CHANGES IN EXECUTIVE TEAM



CorMedix, a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiovascular disease, has made changes to its executive team.

Randy Milby has been promoted to CEO. Mr. Milby was previously chief operating officer.

Antony Pfaffle, M.D., a director on the CorMedix board, joins the executive team as acting chief scientific officer.

### ▶ BIOTECH POOL

**Dr. Stephen HOGÉ**

#### MODERNA THERAPEUTICS CREATES NEW EXECUTIVE POSITION



Moderna Therapeutics, which is developing a new platform designed to spur the body to create its own therapeutic proteins to treat a wide range of diseases, has named Stephen Hoge, M.D., as senior VP of corporate development and new drug concepts.

In this newly created role, Dr. Hoge is leading corporate development efforts, including corporate strategy and business development, as well as working with scientists around the world to develop novel drug concepts enabled by messenger RNA.

Most recently, Dr. Hoge was a partner at McKinsey & Company.

### ▶ DISCOVERY POOL

**Dr. Ben ASKEW**

#### SCIFLUOR LIFE SCIENCES NAMES VP, RESEARCH



SciFluor Life Sciences, a drug discovery and development company harnessing the transformational power of fluorine to accelerate the development of innovative new therapeutics, has named Ben Askew, Ph.D., as VP, research. In this newly created position, Dr. Askew oversees the development and expansion of the company's pipeline of Fluoropeutics, a proprietary portfolio of new chemical entities consisting of fluorinated versions of small-molecule drugs with substantial human clinical or postmarketing experience.

Most recently, Dr. Askew served as entrepreneur-in-residence at Third Rock Ventures, a venture capital firm focused on building life-sciences companies.

### ▶ CRO POOL

**David HERRON**

#### WORLDCARE CLINICAL NEW BUSINESS DEVELOPMENT LEAD



WorldCare Clinical, an imaging CRO, has appointed David Herron as executive VP of business development and corporate strategy. Mr. Herron brings extensive senior management

experience and industry knowledge to WCC having worked in healthcare for more than 20 years. He is responsible for all sales, marketing, and corporate communications activities worldwide, including expanding relations with clients and partners, refining service offerings and driving the company's strategic direction.

### ▶ AGENCY POOL

**Kathryn BAKER**  
**Stacy GORDON**  
**Laura JANSEN**

#### ABELSON TAYLOR PROMOTES THREE



AbelsonTaylor, a Chicago-based advertising agency, has appointed Kathryn Baker, Stacy Gordon, and Laura Jansen to the position of senior account executive. They had previously been account executives.



In her new position, Ms. Baker, who joined AbelsonTaylor in 2008, is focusing her efforts on HCPs and payers in the area of women's health. She holds a B.A., strategic communication, Miami University.



As part of her new responsibilities, Ms. Gordon, who joined AbelsonTaylor in 2008, is coordinating the agency's marketing efforts, including large-scale label and messaging updates. Ms. Gordon holds a BA from Baylor University.

Ms. Jansen, who joined AbelsonTaylor in 2009 after graduating from Colgate University, will be working in the rheumatology area.

**Heather COYLE**  
**Dr. Brian WHALEN**

#### EVOKE INTERACTIONS BOLSTERS HCP MARKETING PRACTICE

Evolve Interaction, a full-service healthcare agency,



has appointed two executives to its existing HCP marketing practice.

Heather Coyle, executive VP, HCP marketing, is the senior executive responsible for guiding the growth of the practice. Brian Whalen, Ph.D., VP, leads all medical and scientific activity. Both executives are based in the company's New York office, managing projects across all regions.

With two decades of global healthcare communications experience, Ms. Coyle has a diverse leadership background in pharmaceutical sales, HCP, DTC, and DTP marketing, digital strategy, payer strategy, medical education, and publication planning.

Dr. Whalen was most recently involved in biomedical research at Harvard and Columbia Universities.

### ▶ ASSOCIATION POOL

**Josef VON RICKENBACH**

#### ACRO NAMES 2013 CHAIR



Parexel Chairman and CEO Josef von Rickenbach has been elected as 2013 chairman of the Association of Clinical Research Organizations (ACRO). Mr. von Rickenbach previously served as chair of ACRO in 2005 and is a long-standing member of the ACRO board of directors.

Since its founding in 2002, ACRO has been committed to highlighting CRO expertise in all aspects of the clinical research enterprise. ACRO represents the CRO industry globally to pharmaceutical, biotech and medical device companies, regulators and legislators, peer associations, academic organizations, patient groups, the media, and the public.

### ▶ CONSULTANT POOL

**Kathryn GALLANT**

#### INSIGHT HEALTH US NAMES CEO



Kathryn Gallant moves to New York-based healthcare research consultancy, Insight Health US, from a key leadership role at Hall & Partners, where she was responsible for managing a broad portfolio of global pharmaceutical clients as well as a large full-service research team across North America.

Ms. Gallant, as joint CEO of Insight Health, brings with her 14 years of experience in market research spanning both global and U.S. healthcare research. She works alongside joint CEO Jessica Cunningham. <sup>PV</sup>



USE YOUR QR CODE READER  
OR GO TO  
[bit.ly/PV0313-TalentPool](http://bit.ly/PV0313-TalentPool)



# Providing solutions to accelerate early drug development

4-6 June 2013, Jumeirah Carlton Tower Hotel, London, UK

Join industry experts to discuss improving translational medicine, developing successful early phase clinical trial designs and proven strategies in assessing proof of concept.

## Over 50 industry speakers confirmed including...



**Dr Bruno Osterwalder**  
SVP, Senior Strategic  
Advisor Oncology  
**Merck Serono**



**Dr Bahija Jallal**  
Executive Vice President  
**Medimmune**



**Dr Yoshiya Oda**  
President of Biomarkers &  
Personalized Medicine  
**Eisai**



Register now  
to secure your place.  
Enter promotion code:  
AD01 when booking.

**Exploratory Clinical**  
**DEVELOPMENT WORLD**  
Europe 2013

[www.healthnetworkcommunications.com/exploratory](http://www.healthnetworkcommunications.com/exploratory)

**2013**  
sponsors



[www.healthnetworkcommunications.com/exploratory](http://www.healthnetworkcommunications.com/exploratory)

## ▶ PHARMA POOL

**Dr. Michael HEFFERNAN**

**Dr. Alisa KOCH**

### LILLY AUGMENTS AUTOIMMUNE TEAM

Eli Lilly and Company has named Michael Heffernan, M.D., a nationally recognized expert in complex medical dermatology, psoriasis, and clinical trials, to its autoimmune team as distinguished medical fellow. Alisa Koch, M.D., a rheumatologist who has won numerous academic awards for her extensive work in rheumatoid arthritis, has joined as senior medical fellow.

Most recently, Dr. Heffernan was in private practice at Central Dermatology in St. Louis, and was formerly the chair of the Department of Dermatology at the Wright State University Boonshoft School of Medicine. He is also a past president and a member of the board of directors of the Medical Dermatology Society. In this new position at Lilly, he will provide scientific and medical direction to those molecules in clinical development for the treatment of psoriasis and other autoimmune dermatological conditions. He will also serve as a senior medical advisor to Lilly's advocacy and medical education efforts in these disease states.

Dr. Koch recently served in an endowed chair position — the Frederick G.L. Huetwell and William D. Robinson, M.D. Professor of Rheumatology — at the University of Michigan Medical School. As senior medical fellow, her key responsibilities are to advance and support the development, launch, and commercialization of the U.S. autoimmune programs. She serves as a representative and advocate for the programs within the rheumatological professional medical community and support Lilly's overall medical education efforts in these disease states.

## ▶ BIOPHARMA POOL

**Dr. Lawson MACARTNEY**

### AMBRX NAMES PRESIDENT AND CEO

Ambrx has appointed Lawson Macartney, Ph.D., to

president and CEO and a member of the board of directors.

Dr. Macartney brings more than 20 years of experience in the pharmaceutical industry, including recent work growing and diversifying the clinical pipeline of Shire Pharmaceuticals as senior VP and head of emerging business unit.

Ambrx is a clinical-stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including antibody drug conjugates, bispecific antibodies and proteins with improved pharmacologic properties.

**Dr. Bruce SCHNEIDER**

### OMNI BIO PHARMACEUTICAL APPOINTS NEW CEO

Omni Bio Pharmaceutical Inc., a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, has appointed Bruce Schneider, Ph.D., as its CEO.

Dr. Schneider also is a member of the company's board of directors.

## ▶ CRO POOL

**Ran FRENKEL**

### CLINIPACE WORLDWIDE MAKES GLOBAL MOVE

Clinipace Worldwide, a global digital contract research organization (dCRO), has expanded Ran Frenkel, R.Ph., VP, international business development, role at the company. Mr. Frenkel has taken on the additional responsibility as managing director, EMEA. Country managers in the region report directly to him in his new role.

**Dr. Dean SHIRAZI**

### AAIPHARMA ANNOUNCES PROMOTION

AAI Pharma Services, a provider of pharmaceutical product development services, has promoted Dean Shirazi, Ph.D., to executive VP of analytical laboratories.

Dr. Shirazi, who has a 20-year career at AAI Pharma, is a recognized expert in multiple types of liquid chromatography and gas chromatography.

## ▶ AGENCY POOL

**Anita BOSE**

**Julia JACKSON**

**Lisa WEISS**

### COONEY/WATERS GROUP ANNOUNCES LEADERSHIP ADDITION AND PROMOTIONS

Cooney/Waters Group (CWG), a healthcare communications group of companies, has named veteran marketing communications leader Anita Bose as chief strategist.

She has responsibility for leading business development initiatives, broadening service offerings across the companies, and working with agency leadership to identify and develop client opportunities. Most recently, Ms. Bose was VP of external communications for inVentiv Health.


The agency group also promoted two long-tenured senior professional service staff, including Julia Jackson to executive VP, Cooney/Waters, and Lisa Weiss to executive VP/group director, Cooney/Waters.

## ▶ SERVICE POOL

**Charlie MORRIS**

### ALMAC'S CLINICAL TECHNOLOGIES NAMES NEW VP

Almac Group's Clinical Technologies business unit welcomes Charlie Morris as VP, new products and services.

In this role, Mr. Morris is charged with overseeing the development of Almac's IXRS technology and enhancing the company's metrics-based discipline to the software development process. 



# it would be the envy of all other green fleet families. if there were any other green fleet families.

Meet the Prius Family. Now there's a Prius that's perfect for every business. All with the low CO<sub>2</sub> emissions, low operating costs and high resale value synonymous with the original. Call 1-800-732-2798 or visit [fleet.toyota.com](http://fleet.toyota.com).



### **prius plug-in hybrid**

Rated up to 95 MPGe,<sup>1</sup> it's our most advanced Prius yet.



### **3rd gen prius**

The hybrid you know and love, updated.



### **prius c**

The city-friendly compact for zipping around town.



### **prius v**

67.3 cubic feet of storage.<sup>2</sup>  
More than most small SUVs.<sup>3</sup>

[fleet.toyota.com](http://fleet.toyota.com)

 **TOYOTA FLEET**

Options shown. <sup>1</sup>2012 EPA combined estimated 95 miles per gallon gasoline equivalent rating. MPGe includes consumption of electricity and gasoline energy during EV Mode. Actual results will vary. See [fuelconomy.gov](http://fuelconomy.gov). <sup>2</sup>Cargo and load capacity limited by weight and distribution. <sup>3</sup>Based on manufacturers' data for cargo volume behind second-row seats; MY 2012 Small SUV segment. ©2012 Toyota Motor Sales, U.S.A., Inc.



— TAKE THE —  
**OPUS**  
**HEALTH**  
**CHALLENGE**

OPUS HEALTH has the perfect equation for designing, implementing and processing co-pay and voucher programs.

We own pharmacy relationships—we're *not a broker*—which enables us to customize solutions in ways other suppliers cannot while providing *significant cost savings*.

**Go ahead, put us to the test.**

We'll run a complimentary analysis demonstrating how we can optimize your current program while reducing costs. Contact us at [challenge@opushealth.com](mailto:challenge@opushealth.com) or 877-OPUSH95.

**OPUS**HEALTH™

A Division of Cegecim Relationship Management

**MORE SAVINGS. MORE SOLUTIONS.**